MX2021014987A - Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas. - Google Patents

Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.

Info

Publication number
MX2021014987A
MX2021014987A MX2021014987A MX2021014987A MX2021014987A MX 2021014987 A MX2021014987 A MX 2021014987A MX 2021014987 A MX2021014987 A MX 2021014987A MX 2021014987 A MX2021014987 A MX 2021014987A MX 2021014987 A MX2021014987 A MX 2021014987A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
huperzine
methods
modified release
same
Prior art date
Application number
MX2021014987A
Other languages
English (en)
Inventor
Peter Goldstein
Stephen D Collins
Joshua T Johnstone
Original Assignee
Biscayne Neurotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biscayne Neurotherapeutics Inc filed Critical Biscayne Neurotherapeutics Inc
Publication of MX2021014987A publication Critical patent/MX2021014987A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud describe composiciones farmacéuticas para la liberación modificada de huperzina. Las composiciones farmacéuticas y métodos descritos en la presente hacen posible la administración de dosis de huperzina en umbrales terapéuticos más elevados al tiempo que se evitan los niveles en plasma máximos en suero rápido, de forma que se evitan las nauseas y vómitos asociados con las composiciones farmacéuticas de liberación inmediata. También se describen métodos para el tratamiento de trastorno neurológicos y/o trastornos convulsivos con las composiciones de liberación modificada.
MX2021014987A 2017-05-19 2019-11-14 Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas. MX2021014987A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508554P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
MX2021014987A true MX2021014987A (es) 2022-02-22

Family

ID=64270169

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019013666A MX2019013666A (es) 2017-05-19 2018-05-21 Composiciones farmacéuticas de liberación modificada de huperzina y métodos para usarlas.
MX2021014987A MX2021014987A (es) 2017-05-19 2019-11-14 Composiciones farmaceuticas de liberacion modificada de huperzina y metodos para usarlas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019013666A MX2019013666A (es) 2017-05-19 2018-05-21 Composiciones farmacéuticas de liberación modificada de huperzina y métodos para usarlas.

Country Status (8)

Country Link
US (2) US20180333365A1 (es)
EP (2) EP4327871A3 (es)
JP (2) JP7317002B2 (es)
CN (2) CN110769816B (es)
AU (2) AU2018270505B2 (es)
CA (1) CA3064006A1 (es)
MX (2) MX2019013666A (es)
WO (1) WO2018213838A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4327871A3 (en) * 2017-05-19 2024-06-05 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US11351120B2 (en) * 2018-11-19 2022-06-07 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
EP0877040B1 (en) 1997-05-09 2000-04-12 Dainippon Ink And Chemicals, Inc. Phenol resin composition and method of producing phenol resin
KR100437105B1 (ko) 1998-12-24 2004-06-23 얀센 파마슈티카 엔.브이. 방출 조절형 갈란타민 조성물
JP2006504795A (ja) 2002-10-03 2006-02-09 サイプレス バイオサイエンス， インコーポレイテッド 神経学的障害を処置するための抗うつ剤の投薬量の段階的な漸増ならびに毎日の分割した投薬
CN1208054C (zh) * 2003-05-27 2005-06-29 解健博 石杉碱甲口服缓释制剂
CN1726911B (zh) 2004-07-27 2010-08-04 中国人民解放军军事医学科学院毒物药物研究所 石杉碱的控释制剂
US20060045865A1 (en) * 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
CN1751683A (zh) 2004-09-21 2006-03-29 山东绿叶制药有限公司 石杉碱甲及其衍生物或其盐的骨架型缓释片及其制备工艺
EP2243475B1 (en) 2005-04-06 2016-01-13 Adamas Pharmaceuticals, Inc. Combination of memantine and donepezil for treatment of CNS disorders
ES2351709T3 (es) * 2005-04-06 2011-02-09 Adamas Pharmaceuticals, Inc. Método y composiciones para el tratamiento de trastornos de sistema nervioso.
JP2008543845A (ja) * 2005-06-16 2008-12-04 フォーレスト ラボラトリーズ， インコーポレイテッド 放出調節および即放性メマンチンビーズ製剤
CN101081217A (zh) 2006-05-30 2007-12-05 上海特敏生物医药科技有限公司 一种含有石杉碱甲的缓释小丸制剂及其制备方法
US8883814B2 (en) * 2006-06-05 2014-11-11 Keyview Labs, Inc. Compositions and methods for enhancing brain function
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
CN101732312A (zh) * 2009-11-27 2010-06-16 武汉益维康医药技术开发有限公司 一种石杉碱甲口服制剂及其制备方法
KR101791715B1 (ko) 2010-02-03 2017-10-30 파마 투 비 엘티디 라사길린의 연장 방출 제형 및 그 용도
EP2560623A1 (en) * 2010-04-22 2013-02-27 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Oral sustained release formulation of huperzine a
CN101987081B (zh) * 2010-07-16 2012-08-08 钟术光 一种控释制剂
CN101919803A (zh) * 2010-07-16 2010-12-22 钟术光 一种控释制剂
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2681199B1 (en) * 2011-03-04 2018-09-26 Yale University Process for the preparation of (-)-huperzine a
WO2013024023A1 (en) 2011-08-12 2013-02-21 Boehringer Ingelheim Vetmedica Gmbh Taste masked pharmaceutical composition
CN102627605B (zh) * 2012-03-22 2014-09-10 中国科学院上海药物研究所 石杉碱甲多晶型体、其制备方法、包含所述多晶型体的药物组合物及其用途
CN103417505B (zh) * 2012-05-24 2016-05-11 中国科学院上海药物研究所 具有双相释药行为的石杉碱甲控释制剂及其制备方法
US20150335624A1 (en) 2013-01-04 2015-11-26 Insero Health Inc. Compositions and methods for using huperzine and analogs thereof
FR3007651A1 (fr) * 2013-06-27 2015-01-02 Assist Publ Hopitaux De Paris Composition pharmaceutique sous forme de granules pour le traitement de desordres metaboliques chez l'enfant
EP4327871A3 (en) * 2017-05-19 2024-06-05 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US11351120B2 (en) * 2018-11-19 2022-06-07 Supernus Pharmaceuticals, Inc. Use of higher doses of modified release huperzine formulations

Also Published As

Publication number Publication date
CN110769816B (zh) 2022-12-06
CN110769816A (zh) 2020-02-07
AU2018270505B2 (en) 2023-09-21
US20210353552A1 (en) 2021-11-18
MX2019013666A (es) 2020-08-20
AU2018270505A1 (en) 2019-12-05
CA3064006A1 (en) 2018-11-22
JP2020520996A (ja) 2020-07-16
WO2018213838A1 (en) 2018-11-22
JP7317002B2 (ja) 2023-07-28
EP3624779B1 (en) 2024-04-03
EP4327871A2 (en) 2024-02-28
CN115715769A (zh) 2023-02-28
EP4327871A3 (en) 2024-06-05
EP3624779A4 (en) 2022-07-06
JP2023134691A (ja) 2023-09-27
AU2023282287A1 (en) 2024-01-18
US20180333365A1 (en) 2018-11-22
EP3624779A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2020001103A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2019010907A (es) Agonistas del receptor x farnesoide, y usos de los mismos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
MX2019001321A (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
MX2021015503A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
MX2021003773A (es) Composiciones farmacéuticas y métodos relacionados con los agentes terapéuticos óticos.
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2019051327A3 (en) BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
MX2020012979A (es) Métodos para aumentar la exposición al plasma de sepiapterina.
MX2020009942A (es) Compuestos y usos de los mismos.
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.